Vyome Biosciences, an innovation-driven dermatology company focused on developing novel and break through treatments for hard to treat and refractory skin conditions such as persistent dandruff and skin fungal infections, resistant acne and other skin bacterial infections, has closed Series B financing of $8 million led by Sabre Partners, with existing Series A investors Kalaari Capital and Aarin Capital also co-investing.
Vyome was co-founded by Dr Shiladitya Sengupta, co-chair at the Centre for Regenerative Therapeutics at Brigham & Women’s Hospital in Boston and assistant professor of Medicine at Harvard Medical School, Dr Rajesh Gokhale, director of the Institute of Genomics and Integrative Biology in Delhi, N Venkat, who earlier worked as Chief Executive Officer, Emami and President, Shantha Biotechnics and Rajiv Mantri Executive Director, Navam Capital.
Vyome is pioneering the development of a deep pipeline of molecules, including ‘first in class’ Molecular Replacement Therapeutics, MRT for killing dandruff-causing fungus, new antibiotics using Dual Action Rational Therapeutics, DART Technology that kill resistant acne-causing bacteria, and has developed a robust global patent portfolio. Vyome recently successfully completed clinical studies on VB001 and VB2421 for mild to moderate dandruff.
Speaking on the occasion, N Venkat, Co-Founder and Chief Executive Officer, Vyome said “This financing is a major landmark in Vyome’s journey to translate cutting edge science into differentiated products and innovative commercialization strategies, and gives the company substantial fire power to drive the completion of critical milestones of US FDA filings and phase I and phase II clinical research for some of its lead compounds and other development and commercialisation efforts of its Rx and OTC pipeline.”
“Four years ago, Vyome set out to do what had never been done in India; that is to create innovation-based products for global markets out of India. Dermatology is one area that has not seen much innovation for over five decades but with the recent advances in science, significantly more effective solutions become possible. This financing is another important milestone in Vyome’s pioneering effort to deliver innovative solutions in dermatology,” said Dr Raghunath Mashelkar, Chairman, Vyome.
“We are delighted to partner with a world-class team that is applying science and critical understanding of unmet needs to develop unique platform technologies and products for the $20 billion global dermatology market,” said Rajiv Maliwal, Founder and Managing Partner, Sabre Partners.
EP News Bureau– Mumbai
